66--Illumina MiSeq i100 Series system

Notice of Intent to Sole Source

This document announces the U.S. Department of the Interior's intent to negotiate a sole source, firm-fixed-price acquisition with Illumina, Inc. for one (1) Illumina MiSeq i100 Plus Sequencing System. This system is intended for the U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR).

The CCR requires this system to replace aging iSeq and legacy MiSeq instruments and to support centralized sequencing operations. The MiSeq i100 Plus is expected to provide improved run reliability, streamlined workflows, and flexible support for small- and mid-scale sequencing projects. Illumina is identified as the sole Original Equipment Manufacturer (OEM) with the capability to provide this specific system, its associated consumables, integrated secondary analysis functionality, and required installation and training services. Procuring from the OEM ensures compatibility with existing government-owned Illumina platforms and avoids operational interruptions.

CCR Genomics Core, National Cancer Institute, 37 Convent Drive, MSC 4256, Bethesda, MD 20892-4256.

While this action is being processed as a sole source, other entities are invited to express their interest and demonstrate their capability by submitting a capability statement. The submission deadline is 10:00 A.M. ET, Monday, April 20, 2026. Submissions must not exceed ten (10) pages and should be in a Microsoft Office compatible format or Adobe Acrobat. The maximum file size is 8 MB. Late responses will only be accepted if they contain extraordinary value. Marketing brochures and generic company literature will not be considered. The Government reserves the right to issue a Request for Quote (RFQ) based on responses received.

Delivery is required no later than 12 weeks after contract award.

Notice of Intent to Sole Source

This notice announces the U.S. Department of the Interior's intent to negotiate a sole source, firm-fixed-price acquisition with Illumina, Inc. The acquisition is for one (1) Illumina MiSeq i100 Plus Sequencing System, including delivery, installation, and training. This system is intended for the U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR).

• One (1) Illumina MiSeq i100 Plus Sequencing System.

• The system is required to replace aging iSeq and legacy MiSeq instruments.

• It will support centralized sequencing operations, improve run reliability, streamline workflows, and provide flexible support for small- and mid-scale sequencing projects.

• The OEM (Illumina) is stated as the only entity with the authorized capability to provide this system, associated consumables compatibility, integrated DRAGEN secondary analysis functionality, and required installation and training services.

• Procuring from the OEM ensures compatibility with existing Government-owned Illumina platforms and avoids interruptions.

• Contract Type: Firm-Fixed-Price (FFP)

• Delivery: No later than 12 weeks after contract award.

• This is a Notice of Intent to Sole Source, not a request for competitive quotes.

• Interested parties may express their interest and demonstrate capability by submitting a capability statement.

• Capability statements are due by 10:00 A.M. ET, Monday, April 13, 2026.

• Submissions should be sent electronically to Bridgette Ornelas (bridgette_ornelas@ibc.doi.gov) and Desmond Harris (desmond_harris@ibc.doi.gov).

• Submissions shall not exceed ten (10) pages and must be in a Microsoft Office compatible format or Adobe Acrobat.

• The maximum file size for submissions is 8 MB.

• The Government will consider capability statements received by the deadline.

• A determination not to compete this action based on responses is solely within the Government's discretion.

• Information received is for determining whether to conduct a competitive acquisition.

• The Government reserves the right to issue an RFQ.

• This is currently intended as a sole source acquisition.

• The Government will not reimburse for any information or administrative costs incurred in response to this notice.

• Marketing brochures and generic company literature will not be considered.

• Not addressing all requested information may result in the Government determining the responder is not capable of performing the scope of work.